Read this article in 中文 Français Deutsch Italiano Português Español
Eli Lilly to construct US$6.5bn Texas pharmaceutical manufacturing site
25 September 2025
US-based drugmaker Eli Lilly has announced plans to build a US$6.5 billion pharmaceutical manufacturing facility near Houston, Texas, expanding its US production network for active pharmaceutical ingredients.
Render of the future Eli Lilly manufacturing facility in Texas, US. Image: Eli Lilly
The site, Lilly’s eighth US manufacturing facility announced since 2020, will produce small-molecule synthetic medicines, including the company’s pipeline treatments for cardiometabolic health, oncology, immunology, neuroscience and obesity.
Construction will create about 4,000 jobs, with 615 permanent positions to follow in engineering, operations and laboratory work. Lilly said the facility should be operational within five years.
Lilly said the project will incorporate digital automation, advanced analytics and AI systems across its production lines. The company will also work with Texas universities on workforce development and invest in educational initiatives to build local talent pipelines.
The Texas facility is the second of four new US manufacturing sites Lilly has committed to build this year, following a recent announcement in Virginia.
STAY CONNECTED
Receive the information you need when you need it through our world-leading magazines, newsletters and daily briefings.
CONNECT WITH THE TEAM
